DP

Deepika Punnapu

Active Director Director DIN 09353647
DIN 09353647 First appointment Aug 2022 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Aug 2022
Shareholding value •••• Premium profile

About Deepika Punnapu

Data last updated:

Deepika Punnapu is a Director at Sinterx Pharma Private Limited (since 2022). The company operates in Pharma. Sinterx Pharma Private Limited reported revenue of ₹74.65 Cr (FY 2025).

DIN 09353647
Primary Designation Director
Industry Pharma
First Appointment 26 Aug 2022
Oldest Company Age 5 yrs
Largest company Sinterx Pharma Private Limited · ₹74.65 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Sinterx Pharma Private Limited U24299TG2021PTC154397
Director26 Aug 20222021₹74.65 Cr (FY 2025)Active

Board colleagues of Deepika Punnapu

Directorship timeline

Open interactive timeline →
Sinterx Pharma Private Limited
Premium access

Shareholding and investment profile for Deepika Punnapu

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Deepika Punnapu

Deepika Punnapu currently holds 1 directorship: Sinterx Pharma Private Limited (Director, since 26 Aug 2022, revenue ₹74.65 Cr (FY 2025)).

Deepika Punnapu was first appointed on 26 Aug 2022 as Director at Sinterx Pharma Private Limited.

The current boards of Deepika Punnapu's companies include Golla Padmavathi (Sinterx Pharma Private Limited), Sruthi Medapati (Sinterx Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available